ArticleBrain tumor pathology2026
Tectal glioma with pilocytic astrocytoma morphology carrying a histone H3 K27M mutation and malignant transformation: a literature review.
Article in Brain tumor pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We report a case with pilocytic astrocytoma (PA) morphology carrying a histone H3 K27M mutation (H3-K27M) that progressed to PA with anaplasia. A 34-year-old woman presented with headache due to obstructive hydrocephalus from a tectal lesion. She underwent subtotal tumor resection. Histology showed a biphasic architecture with piloid cells, consistent with PA. Five months later, she developed recurrence. A second, partial resection was performed, with pathology again indicating PA. Despite subsequent radiation and chemotherapy, the tumor progressed. A third resection was done 15 months after the second. This time, histology revealed PA with anaplasia. The patient died of progressive disease 25 months after initial treatment. KIAA1549::BRAF fusion, H3-K27M, and loss of p16 expression due to promoter methylation were detected in all specimens. In all specimens, the presence of NF1 Y2285fs*1 was confirmed by Sanger sequencing, with an increasing proportion of the aberrant sequence at the third resection. DNA methylation profiling revealed that the second and third specimens were classified as diffuse midline glioma, H3 K27-altered. This case suggests that the H3-K27M mutation, MAPK pathway activation, and loss of p16 expression contribute to tumorigenesis, while clonal proliferation of the tumor harboring the NF1 mutation may play a role in malignant progression.
Indexed as
Identifiers
42120807What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.